NCT06433219 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT06433219
Title	Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)
Acronym	DDRiver EOC 302
Recruitment	Active, not recruiting
Gender	female
Phase	Phase II
Variant Requirements	No
Sponsors	EMD Serono Research & Development Institute, Inc.
Indications	endometrioid ovary carcinoma ovarian serous carcinoma peritoneal serous adenocarcinoma fallopian tube endometrioid adenocarcinoma fallopian tube cancer peritoneum cancer fallopian tube serous adenocarcinoma ovary epithelial cancer
Therapies	M1774 M1774 + Niraparib Lartesertib + M1774
Age Groups:	adult \| senior
Covered Countries	USA \| POL \| NLD \| ITA \| ISR \| GBR \| FRA \| ESP \| DNK \| DEU \| CHE \| BEL \| AUS

No variant requirements are available.